Culley Brian M's Form 4 filing
Lineage Cell Therapeutics, Inc.LCTX · filed Apr 4, 2022
- Accession no.
- 0001493152-22-009000
- Filed
- Apr 4, 2022
- Trade date
- Mar 31, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market purchases total $9.79K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Culley Brian MCIK 0001310683 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2022 | Common Shares, no par value | MOption exerciseAcquired | +15,450 | –F1 | – | 96,730 | Direct | |
| Mar 31, 2022 | Common Shares, no par value | FTax withholdingDisposed | −5,343 | $1.54 | −$8,228.22 | 91,387 | Direct | |
| Mar 31, 2022 | Common Shares, no par value | PPurchaseAcquired | +6,400 | $1.53F4 | +$9,792 | 97,787 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2022 | Common Shares | MOption exerciseDisposed | −15,450 | $0.00 | $0 | 15,450 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.52 to not more than $1.54. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
Referenced by the price of 1 transaction in Table I.